MG

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Thursday, May 9, 2024
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Investment, Teclistamab, Partnership, Myasthenia gravis, Trial of the century, Growth, Hook effect, ASCO, Journal, Lung cancer, Graves' ophthalmopathy, Pharmacokinetics, National Medical Products Administration, Conference, Fluorouracil, Patent, Telephone, NSCLC, Merck Group, Safety, Pembrolizumab, Artificial intelligence, CEACAM5, Autoimmune disease, Immunology, Monoclonal antibody, Clinical trial, University, TED, Sale, Chicken, Bystander effect, Antigen, Neonatal Fc receptor, Patient, Society, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.
  • “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base.
  • General and administrative expense was $8.3 million for the first quarter of 2024, compared with $8.2 million for the same period in 2023.
  • As of March 31, 2024, OmniAb had cash, cash equivalents and short-term investments of $69.0 million.

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 8, 2024
Corporate headquarters, FDA, Multiple myeloma, Safety, Risk, Pharmacokinetics, Food, Research, Orphan, Cell, CGMP, Autoimmune disease, Patient, Gene, Society, Messenger, SLE, Therapy, BCMA, Growth, Pharmaceutical industry

GAITHERSBURG, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today reported financial results for the first quarter ended March 31, 2024, and recent corporate updates.

Key Points: 
  • Recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of MG.
  • Dosing of first patient in Phase 2 trial of Descartes-08 in patients with SLE expected in second quarter of 2024.
  • Transitioning Corporate Headquarters to Frederick, Maryland
    In March 2024, the Company announced plans to transition its corporate headquarters to Frederick, Maryland.
  • General and administrative expenses were $9.5 million for the quarter ended March 31, 2024, compared to $5.7 million for the quarter ended March 31, 2023.

MISTRAS Group to Participate in Sidoti Micro-Cap Virtual Investor Conference on May 8-9, 2024

Retrieved on: 
Friday, May 3, 2024
Interim, Senior, Conference, Safety

The presentation will begin at 10:00 AM ET on Thursday, May 9, 2024.

Key Points: 

Myasthenia Gravis Foundation of America (MGFA) Kicks off Annual National MG Patient Conference With Program Announcements

Retrieved on: 
Monday, April 29, 2024
Online, Education, FDA, Patient, Language, Learning, Social work, Muscle weakness, Myasthenia gravis, Conference, Convention center, Myasthenia, Research, Human, Neurology, Disease, Registry, Fatigue, Caregiver, Community, Quality of life, MGFA, Nursing

TAMPA BAY, Fla., April 29, 2024 /PRNewswire/ -- More than 400 members of the myasthenia gravis (MG) rare disease community will come together this week at the MGFA National Patient Conference for support and a better understanding of how to manage their disease while learning about the latest in treatments and clinical studies.  

Key Points: 
  • Myasthenia Gravis Foundation of America (MGFA™) , the largest, leading patient advocacy organization solely dedicated to the myasthenia gravis community kicked off its annual conference today with a volunteer awards dinner and new program announcements.
  • The conference features patient stories and individuals diagnosed with myasthenia gravis as well as presentations and discussions from patients, caregivers, researchers, MG expert clinicians, and pharmaceutical and industry partners.
  • Bringing together MG patients and other members of the community to learn from and support each other is so powerful," said Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America.
  • MGFA Global MG patient Registry – The MGFA Global MG Patient Registry gives the MG community a loud voice in ensuring that research studies and clinical trials are built to evaluate the most promising MG research.

MISTRAS Group Announces Conference Call to Discuss First Quarter Results on May 2, 2024

Retrieved on: 
Friday, April 26, 2024

PRINCETON JUNCTION, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE) has scheduled a conference call for Thursday, May 2, 2024 at 9:00 am Eastern Time to discuss its results for the first quarter of 2024.

Key Points: 
  • PRINCETON JUNCTION, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE) has scheduled a conference call for Thursday, May 2, 2024 at 9:00 am Eastern Time to discuss its results for the first quarter of 2024.
  • A press release with the first quarter results will be issued after the close of market on Wednesday, May 1, 2024.
  • To listen to the live webcast of the conference call, visit the Investor Relations section of MISTRAS Group’s website at www.mistrasgroup.com .
  • Following the conference call, an archived webcast of the call will be available for one year by visiting the Investor Relations section of MISTRAS Group’s website.

Radial Equity Partners Announces New Partnership with Moss Motors and Rimmer Bros

Retrieved on: 
Wednesday, April 17, 2024
Vehicle Technology, Aftermarket, Automotive, Other Automotive, General Automotive, Performance & Special Interest, Fleet Management, Investment, MX-5, Mini, Land Rover, Rover, History, Austin-Healey, Multimedia, Marketing, Partner

Radial Equity Partners (“Radial”) announced on April 12, 2024 simultaneous investments in Moss Motors (“Moss”) and Rimmer Bros (“Rimmer Bros”) to form a leading, global specialty supplier of restoration & replacement parts focused on British vehicle brands.

Key Points: 
  • Radial Equity Partners (“Radial”) announced on April 12, 2024 simultaneous investments in Moss Motors (“Moss”) and Rimmer Bros (“Rimmer Bros”) to form a leading, global specialty supplier of restoration & replacement parts focused on British vehicle brands.
  • Rimmer Bros is a UK-based supplier of replacement parts for UK marque vehicles, including Jaguar, Land Rover, MG, Mini, Rover and Triumph.
  • Founded in 1982, Rimmer Bros maintains a comprehensive product library of over 50,000 SKUs sold primarily on a direct-to-consumer basis.
  • The combination of Moss and Rimmer Bros represents the fourth platform investment the Radial team has led in the vehicle aftermarket.

GotIt! Education Offers MathGPT™ Free to All State and Community Colleges in the US - First Agent based, Accuracy-Driven Gen AI Teacher Assistant and Tutor for Any Math Classroom

Retrieved on: 
Wednesday, April 10, 2024
Education, Lecture, Textbook, Essential, Statistics, Education minister, AI, Teaching, School, OpenAI, Management, Tutoring, Sociology, STEM, Gen, PDF, Engineering, Synthetic media, Psychology, OpenStax, Machine learning, Nursing, GM, Aircraft pilot, PALO, Trust, Khan Academy, LMS, Generative, Student

"Too many schools can't afford AI," said Peter Relan, Chairman of, and investor in GotIt! Education. "With MathGPT now free, schools can try AI-based tutors -- but without a hit on already tight budgets.  Our free MathGPT Essentials program also enables schools to switch from poorly functioning AI tutors that are actually slowing adoption of AI technology in education."

Key Points: 
  • "With MathGPT now free, schools can try AI-based tutors -- but without a hit on already tight budgets.
  • Our free MathGPT Essentials program also enables schools to switch from poorly functioning AI tutors that are actually slowing adoption of AI technology in education."
  • Course Management - the ability to create customized courses by uploading a set of educational content which will automatically get incorporated; 2.
  • Grounded AI Tutor - an accurate, personalized, infinitely patient, AI tutor with student input evaluation/correction for each step.

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
Research, MPV, IIM, MuSK protein, Toxicity, Conference, Disease, Dermatomyositis, Juvenile dermatomyositis, Federation, Patient, NOL, Observation, CRS, SLE, Health Canada, IND, Immunoglobulin therapy, Pemphigus, Investment, Investigational New Drug, Myopathy, Systemic scleroderma, Marketing, FDA, Clinical trial, Cytokine release syndrome, Cyclophosphamide, CD19, Food, Autoimmune disease, Pharmaceutical industry

In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.

Key Points: 
  • In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.
  • In November 2023, Cabaletta announced that its IND application for CABA-201 was allowed to proceed by the FDA for the Phase 1/2 RESET-MG trial.
  • Cabaletta anticipates reporting initial clinical data from the Phase 1/2 RESET-MG trial in the second half of 2024.
  • As of December 31, 2023, Cabaletta had cash, cash equivalents and short-term investments of $241.2 million, compared to $106.5 million as of December 31, 2022.

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine

Retrieved on: 
Thursday, March 21, 2024
MuSK protein, Exercise, Science Translational Medicine, Charcot–Marie–Tooth disease, NMD, Patient, Brain cell, Human, Myasthenia gravis, Spinal muscular atrophy, Acetylcholine receptor, Facial muscles, QMG, Myasthenia, Safety, Aarhus University, Muscle weakness, Fatigue, Paper, Neuromuscular disease, Pharmaceutical industry

NMD Pharma’s lead development candidate, NMD670, a novel, selective, and orally bioavailable ClC-1 inhibiting small molecule, is used in the preclinical and clinical studies.

Key Points: 
  • NMD Pharma’s lead development candidate, NMD670, a novel, selective, and orally bioavailable ClC-1 inhibiting small molecule, is used in the preclinical and clinical studies.
  • NMD670 is a muscle-targeted therapy which aims to enhance the activation of skeletal muscle fibers and to improve muscle strength and endurance.
  • As a result, patients have impaired skeletal muscle function and often experience severe muscle weakness and fatigue.
  • Access the full paper in Science Translational Medicine online here:
    In October 2022, NMD Pharma announced positive topline data which established the first clinical proof-of-mechanism of NMD Pharma’s novel CIC-1 chloride channel inhibitor approach in patients impacted by MG.

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine

Retrieved on: 
Thursday, March 21, 2024
MuSK protein, Exercise, Science Translational Medicine, Charcot–Marie–Tooth disease, NMD, Patient, Brain cell, Human, Myasthenia gravis, Spinal muscular atrophy, Acetylcholine receptor, Facial muscles, QMG, Myasthenia, Safety, Aarhus University, Muscle weakness, Fatigue, Paper, Neuromuscular disease, Pharmaceutical industry

NMD Pharma’s lead development candidate, NMD670, a novel, selective, and orally bioavailable ClC-1 inhibiting small molecule, is used in the preclinical and clinical studies.

Key Points: 
  • NMD Pharma’s lead development candidate, NMD670, a novel, selective, and orally bioavailable ClC-1 inhibiting small molecule, is used in the preclinical and clinical studies.
  • NMD670 is a muscle-targeted therapy which aims to enhance the activation of skeletal muscle fibers and to improve muscle strength and endurance.
  • As a result, patients have impaired skeletal muscle function and often experience severe muscle weakness and fatigue.
  • Access the full paper in Science Translational Medicine online here:
    In October 2022, NMD Pharma announced positive topline data which established the first clinical proof-of-mechanism of NMD Pharma’s novel CIC-1 chloride channel inhibitor approach in patients impacted by MG.